Estimation of serum malondialdehyde in oral cancer and precancer and its association with healthy individuals, gender, alcohol, and tobacco abuse

Background: Tobacco and alcohol induces generation of free radicals and reactive oxygen species, which are responsible for high rate of lipid peroxidation. Malondialdehyde is the most widely used marker of lipid peroxidation. The aim of the study was to estimate serum malondialdehyde level in oral precancer, oral cancer, and normal individuals. Materials and Methods: In this study serum malondialdehyde was measured according to the method of Ohkawa et al in 30 normal individuals and 30 patients each with histopathologically diagnosed oral precancer, and oral cancer. Results: The mean serum malondialdehyde level in the control group was found to be 5.107 ± 2.32 ηmol/ml, whereas it was 9.33 ± 4.89 ηmol/ml and 14.34 ± 1.43 ηmol/ml in oral precancer and oral cancer, respectively. There was statistically significant increase in serum malondialdehyde levels in the oral precancer and oral cancer patients compared with the control group. Conclusion: Increased serum malondialdehyde in oral cancer and oral precancer would serve as a valuable marker for both preventive and clinical intervention, and may deserve further investigation for the early diagnosis, treatment, and prognosis

Estimation of serum malondialdehyde in oral cancer and precancer and its association with healthy individuals, gender, alcohol, and tobacco abuse

Background: Tobacco and alcohol induces generation of free radicals and reactive oxygen species, which are responsible for high rate of lipid peroxidation. Malondialdehyde is the most widely used marker of lipid peroxidation. The aim of the study was to estimate serum malondialdehyde level in oral precancer, oral cancer, and normal individuals. Materials and Methods: In this study serum malondialdehyde was measured according to the method of Ohkawa et al in 30 normal individuals and 30 patients each with histopathologically diagnosed oral precancer, and oral cancer. Results: The mean serum malondialdehyde level in the control group was found to be 5.107 \ub1 2.32 \u3b7mol/ml, whereas it was 9.33 \ub1 4.89 \u3b7mol/ml and 14.34 \ub1 1.43 \u3b7mol/ml in oral precancer and oral cancer, respectively. There was statistically significant increase in serum malondialdehyde levels in the oral precancer and oral cancer patients compared with the control group. Conclusion: Increased serum malondialdehyde in oral cancer and oral precancer would serve as a valuable marker for both preventive and clinical intervention, and may deserve further investigation for the early diagnosis, treatment, and prognosis

Oxcarbazepine: Drug of the future in the treatment of trigeminal neuralgia

Background: The aim of the study was to estimate the efficacy of oxcarbazepine in trigeminal neuralgia. Oxcarbazepine is a novel antiepilepfic drug, and its effect on trigeminal neuralgia has not been studied extensively previously. Materials and methods: Fifty-three patients with trigeminal neuralgia (34 men and 19 women) took a mean dose of 600 mg of oxcarbazepine for a period of three weeks. Pain intensity was measured by using visual analog scale. Results: Of the 53 patients, 42 (79%) were completely or well controlled by OXC, and nine (17%) partially but acceptably controlled. Treatment with OXC was therefore satisfactory initially in 51 (96%) of the patients. In seven of these patients, mild transient side effects occurred but did not necessitate cessation of treatment Conclusion: OXC appears to be an effective substitute for carbamazepine in those patients intolerant of this agent, or experiencing significant side effects